{"filing":{"accession_number":"0001193125-26-396644","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-17","primary_document":"d178611d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/d178611d8k.htm"},"events":[{"id":33959,"run_id":31263,"accession_number":"0001193125-26-396644","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Sangamo Therapeutics filed for Chapter 11 bankruptcy protection, as disclosed under Item 1.03.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37560,"accession_number":"0001193125-26-396644","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Item 1.03 is the dedicated 8-K section for bankruptcy or receivership filings. The section header explicitly states \"Bankruptcy or Receivership\" and references Item 2.01, which typically contains material acquisition or disposition details. A bankruptcy filing is a terminal event materially affecting the registrant's continued existence and would be disclosed under this Item.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:10.985689+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":33960,"run_id":31263,"accession_number":"0001193125-26-396644","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Sangamo completed the sale of substantially all assets to PTC Therapeutics for $111 million in cash plus up to $100 million in contingent consideration pursuant to a court-approved Asset Purchase Agreement dated August 25, 2026.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37561,"accession_number":"0001193125-26-396644","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses completion of a sale of substantially all assets to PTC Therapeutics for $111 million in cash plus up to $100 million in contingent consideration, pursuant to a court-approved Asset Purchase Agreement dated August 25, 2026. While this occurs within a Chapter 11 bankruptcy context, the core event is a material disposition of assets meeting Item 2.01 criteria. The bankruptcy context creates some ambiguity about whether to classify this as `ma_activity` versus `bankruptcy_filing`, but the filing's Item designation and focus on the asset sale completion support `ma_activity` as the primary event being disclosed here.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:10.985689+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37560,"accession_number":"0001193125-26-396644","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Item 1.03 is the dedicated 8-K section for bankruptcy or receivership filings. The section header explicitly states \"Bankruptcy or Receivership\" and references Item 2.01, which typically contains material acquisition or disposition details. A bankruptcy filing is a terminal event materially affecting the registrant's continued existence and would be disclosed under this Item.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:10.985689+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-21"},{"id":37561,"accession_number":"0001193125-26-396644","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses completion of a sale of substantially all assets to PTC Therapeutics for $111 million in cash plus up to $100 million in contingent consideration, pursuant to a court-approved Asset Purchase Agreement dated August 25, 2026. While this occurs within a Chapter 11 bankruptcy context, the core event is a material disposition of assets meeting Item 2.01 criteria. The bankruptcy context creates some ambiguity about whether to classify this as `ma_activity` versus `bankruptcy_filing`, but the filing's Item designation and focus on the asset sale completion support `ma_activity` as the primary event being disclosed here.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:03:10.985689+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-21"}]}